Almotriptan dosage and administration: Difference between revisions
(Created page with "__NOTOC__ {{Almotriptan}} {{CMG}}; {{AE}} {{PB}} ==Dosage and Administration== ==References== {{Reflist|2}} Category:AntiMigaraineDrugs Category:Drugs") |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 6: | Line 6: | ||
* Adults and adolescents age 12 to 17 years: 6.25 mg or 12.5 mg single dose; may repeat after 2 hours if headache returns; benefit of second dose in patients who have failed to respond to first dose has not been established; maximum daily dose 25 mg | |||
* Patients with hepatic or severe renal impairment: 6.25 mg starting dose; maximum daily dose 12.5 mg | |||
===Acute Treatment of Migraine Attacks=== | |||
The recommended dose of Almotriptan (almotriptan malate) in adults and adolescents age 12 to 17 years is 6.25 mg to 12.5 mg, with the 12.5 mg dose tending to be a more effective dose in adults. As individuals may vary in their response to different doses of Almotriptan, the choice of dose should be made on an individual basis. | |||
If the headache is relieved after the initial Almotriptan dose but returns, the dose may be repeated after 2 hours. The effectiveness of a second dose has not been established in placebo-controlled trials. The maximum daily dose should not exceed 25 mg. The safety of treating an average of more than four migraines in a 30-day period has not been established. | |||
== | |||
===Hepatic Impairment=== | |||
The recommended starting dose of Almotriptan in patients with hepatic impairment is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour period [seeWarnings and Precautions (5.8) and Clinical Pharmacology | |||
===Renal Impairment=== | |||
The recommended starting dose of Almotriptan in patients with severe renal impairment is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour period [seeWarnings and Precautions (5.8) and Clinical Pharmacology (''' | |||
==References== | ==References== | ||
| Line 12: | Line 30: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Latest revision as of 02:19, 5 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
Dosage and Administration
- Adults and adolescents age 12 to 17 years: 6.25 mg or 12.5 mg single dose; may repeat after 2 hours if headache returns; benefit of second dose in patients who have failed to respond to first dose has not been established; maximum daily dose 25 mg
- Patients with hepatic or severe renal impairment: 6.25 mg starting dose; maximum daily dose 12.5 mg
Acute Treatment of Migraine Attacks
The recommended dose of Almotriptan (almotriptan malate) in adults and adolescents age 12 to 17 years is 6.25 mg to 12.5 mg, with the 12.5 mg dose tending to be a more effective dose in adults. As individuals may vary in their response to different doses of Almotriptan, the choice of dose should be made on an individual basis.
If the headache is relieved after the initial Almotriptan dose but returns, the dose may be repeated after 2 hours. The effectiveness of a second dose has not been established in placebo-controlled trials. The maximum daily dose should not exceed 25 mg. The safety of treating an average of more than four migraines in a 30-day period has not been established. ==
Hepatic Impairment
The recommended starting dose of Almotriptan in patients with hepatic impairment is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour period [seeWarnings and Precautions (5.8) and Clinical Pharmacology
Renal Impairment
The recommended starting dose of Almotriptan in patients with severe renal impairment is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour period [seeWarnings and Precautions (5.8) and Clinical Pharmacology (